Table 3.

Individual Participant Data (IPD) Meta-Analyses: Efficacy Outcomes

Mean Percent of Abstinent Days
Acamprosate = 51.24 (40.95)
Placebo = 42.96 (40.31)
	Incremental Value	95% CI		P-value
Gender	−0.88	−3.09	1.32	0.55
Treatment	10.38	7.10	13.65	<.001
Treatment x Gender	0.12	−4.27	4.12	0.95
Rate of Continuous Abstinence
Acamprosate = 28% (45)
Placebo = 19% (39)
	Odds Ratio	95% CI		P-value
Gender	0.83	0.66	1.04	0.11
Treatment	1.87	1.57	2.23	<.001
Treatment x Gender	1.14	0.84	1.54	0.41
Mean Percent of No Heavy Drinking Days
Acamprosate = 62.78 (39.91)
Placebo = 52.95 (40.99)
	Incremental Value	95% CI		P-value
Gender	−0.16	−3.55	3.24	0.93
Treatment	11.03	7.45	14.62	<.001
Treatment x Gender	1.33	−3.36	6.02	0.58
Rate of No Heavy Drinking
Acamprosate = 39% (49)
Placebo = 28% (45)
	Odds Ratio	95% CI		P-value
Gender	1.00	0.88	1.14	0.99
Treatment	1.93	1.62	2.31	<.001
Treatment x Gender	1.11	0.84	1.34	0.49